CLAIMS

1. Use of a dipeptidyl peptidase-4 (DPP-4) inhibitor for the manufacture of a medicament for preventing or treating aortic valvular calcification.

2. The use of claim 1, wherein the DPP-4 inhibitor is an inhibitor for inhibiting expression of a DPP-4 nucleotide or an inhibitor for inhibiting activity of a DPP-4 protein.

3. The use of claim 2, wherein the inhibitor for inhibiting the expression of the DPP-4 nucleotide sequence is at least one selected from the group consisting of an antisense nucleotide, an aptamer, small interfering RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), and RNA interference (RNAi) against mRNA of the DPP-4.

4. The use of claim 2, wherein the inhibitor for inhibiting the activity of the DPP-4 protein is at least one selected from the group consisting of an antibody against DPP-4, sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, anagliptin, evogliptin, berberine, diprotin, and lupeol.

5. The use of claim 1, wherein the valvular calcification is caused by at least one selected from the group consisting of a valvular disease, hyperlipidaemia, senility, estrogen deficiency, angina, heart failure, nephritis, uremia, diabetes, an inflammatory disease, and a cardiovascular disease.

6. Use of a dipeptidyl peptidase-4 (DPP-4) inhibitor for the manufacture of a food composition for prevention or improvement of aortic valvular calcification.